Close Menu

This article has been updated with comments from an internal Illumina e-mail.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche will not extend its tender offer for Illumina, the Swiss pharmaceuticals and diagnostics firm said today, ending its hostile bid for the San Diego firm for now.

With Illumina's annual shareholder meeting taking place this morning, Roche said that it will not extend its $51-per-share cash tender offer for all shares of Illumina and will let the offer expire at 6 p.m., Friday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

Jul
23
Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.